New Diabetic foot ulcer treatment.
The innovative polymer-coated silicon wound dressing CYP-006TK contains the company’s proprietary Cymerus mesenchymal stem cells, or ‘MSCs’, for topical application to wounds.
Initial patients have enrolled in the four-week treatment period with the study of a proposed 30 adult patient-groups expected to be concluded in six months.
The wound dressing technology is licenced from leading manufacturer of innovative biomedical coatings, TekCyte Limited, and seeded with Cynata’s proprietary therapeutic stem cell platform technology Cymerus.
The company said Cymerus resolve issues facing other cell therapy production methods by using induced pluripotent stem cells and a precursor cell known as mesenchymoangioblast to achieve the economic manufacture of cell therapy products, including MSCs, at a commercial scale without the limitation of multiple donors.
“We are pleased with enrollment of subjects following the commencement of the trial in late December. COVID-19-related changes to patient management at the study sites, initiated shortly after the trial opened, posed a significant number of unforeseen challenges which had a serious impact on enrollment rates. Fortunately, these challenges have now been addressed”, Cynata Therapeutics Chief Medical Officer, Dr Jolanta Airey.
Dr. Airey says the company has also implemented several strategies, such as widening recruitment criteria, that is intended to accelerate the recruitment of trial patients.
According to management Cynata continues to work closely with Professor Fitridge and the Central Adelaide Local Health Network to ensure the trial is completed later this year.